8-K: PDS Biotech Unveils Durable Overall Survival Data for Versamune HPV in Head and Neck Cancers at ASCO 2025

PDS Biotechnology Corporation announced updated positive data from its VERSATILE-002 trial and other studies for Versamune HPV (PDS0101) in treating HPV16-positive head and neck cancers, presented at the 2025 ASCO Annual Meeting.

Summary

• PDS Biotechnology Corporation announced the publication of three Versamune HPV abstracts on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website.
• These abstracts summarize Versamune HPV (PDS0101) studies that were presented during the Head and Neck Cancer Poster Session taking place from May 30-June 3, 2025, in Chicago, Illinois.
• The VERSATILE-002 trial, evaluating Versamune HPV with pembrolizumab for HPV16-positive recurrent/metastatic (1L r/m) HNSCC, showed a median overall survival (mOS) of 30.0 months.
• This mOS has remained durable over the last 1.5 years, with additional follow-up of approximately 4.5 months beyond the initial abstract.
• The lower limit of the 95% confidence interval for mOS increased from 18.4 months in 2023 to 23.9 months as the data matured.
• Enrollment in the VERSATILE-002 trial (n=53) is complete, with 22 patients (including 3 still on treatment) continuing to be followed for survival.
• No new safety signals have emerged from the trial.
• HPV16-positive HNSCC is identified as a rapidly growing and severe medical need, estimated to account for over 50% of head and neck squamous cell carcinoma cases in the US.
• VERSATILE-003 is highlighted as the only ongoing Phase 3 clinical trial exclusively addressing 1L r/m HPV16-positive HNSCC.

Sentiment

Score: 8

Explanation: The document presents highly positive clinical trial data, particularly the durable and superior median overall survival compared to existing treatments for a rapidly growing and severe medical need. The focus on a specific, well-defined patient population and the progression to a pivotal Phase 3 trial are strong indicators of positive momentum. The absence of new safety signals further enhances the positive sentiment.

Positives

• Median overall survival (mOS) in the VERSATILE-002 trial remained durable at 30.0 months, with an extended follow-up of approximately 4.5 months.
• The lower limit of the 95% confidence interval for mOS increased from 18.4 months in 2023 to 23.9 months, indicating data maturation and increased confidence.
• The 30.0 months mOS for Versamune HPV with pembrolizumab in 1L r/m HNSCC (CPS ≥ 1) compares favorably to the longest published mOS of 17.9 months for pembrolizumab monotherapy and combinations in similar patients.
• No new safety signals emerged from the VERSATILE-002 trial.
• PDS Biotech's VERSATILE-003 is the only ongoing Phase 3 clinical trial exclusively targeting 1L r/m HPV16-positive HNSCC, addressing a specific and growing medical need.
• The company's therapeutic approach specifically targets HPV16, which is the most carcinogenic type of HPV and has been reported to suppress the immune system's ability to respond to the virus.

Risks

• The Company's ability to protect its intellectual property rights.
• The Company's anticipated capital requirements, including its anticipated cash runway and plans for future equity financings.
• The Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to its technologies or product candidates.
• The Company's limited operating history in its current line of business, which makes it difficult to evaluate its prospects, its business plan or the likelihood of its successful implementation of such business plan.
• The timing for the Company or its partners to initiate the planned clinical trials for Versamune HPV, PDS01ADC and other Versamune based product candidates.
• The future success of such trials.
• The successful implementation of the Company's research and development programs and collaborations, including any collaboration studies concerning Versamune HPV, PDS01ADC and other Versamune based product candidates and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company's product candidates.
• The success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials, futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (which are not necessarily indicative of the final results of the Company's ongoing clinical trials).
• Any Company statements about its understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies.
• The Company's ability to continue as a going concern.
• Other factors, including legislative, regulatory, political and economic developments not within the Company's control.

Future Outlook

PDS Biotechnology looks forward to the randomized Phase 3 trial (VERSATILE-003), which is the only ongoing registrational trial specifically addressing the rapidly growing population of HPV16-positive HNSCC patients. The company also anticipates two interim survival data readouts from the ongoing Phase 3 study, as well as the final overall survival results.

Management Comments

• "HPV-positive HNSCC is today seen as a different disease from HPV-negative HNSCC. HPV-positive HNSCC has different biological characteristics and requires a more targeted approach that treats the underlying HPV integration and persistence into the patients tumor DNA. Cytotoxic drugs and the EGFR inhibitor cetuximab have not worked as well in HPV-positive HNSCC to date." Kevin Harrington, M.D., Ph.D. of The Institute of Cancer Research.
• "The mOS results are highly encouraging in patients with advanced HPV Type 16-positive HNSCC. This is great news for patients, and we are encouraged that mOS has remained durable over the last 1.5 years. We look forward to the randomized Phase 3 trial, which is the only ongoing registrational trial to specifically address this rapidly growing population of patients." Jared Weiss, M.D., Principal Investigator of the VERSATILE-002 Phase 2 clinical trial.
• "We are very pleased with the overall survival (OS) results. As stated in a 2023 Journal of Clinical Oncology article authored by the FDA, OS is considered the gold standard for oncology approvals. The article discussed the discordance between ORR, PFS and OS. In recently published registrational 1L r/m HNSCC studies, improved ORR and PFS have not translated to improved OS. We look forward to the two interim survival data readouts from the ongoing Phase 3 study as well as the final OS results." Dr. Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech.

Industry Context

The announcement highlights the growing recognition of HPV16-positive HNSCC as a distinct and rapidly increasing disease with specific treatment needs, differentiating it from HPV-negative HNSCC. PDS Biotech's focus on HPV16-specific immunotherapy positions it to address this unmet medical need, contrasting with broader EGFR bispecific antibody approaches that have shown less efficacy in HPV-positive cases. The FDA's recommendation for a companion diagnostic for HPV16-positive HNSCC underscores the industry's move towards more precise, targeted therapies in oncology.

Comparison to Industry Standards

• The median overall survival (mOS) of 30.0 months for Versamune HPV with pembrolizumab in 1L r/m HNSCC (CPS ≥ 1) significantly exceeds the longest published mOS of 17.9 months reported to date with pembrolizumab monotherapy and combinations in patients with 1L r/m HNSCC and CPS ≥ 1.
• PDS Biotech's VERSATILE-003 trial is noted as the only ongoing Phase 3 clinical trial exclusively addressing 1L r/m HPV16-positive HNSCC, distinguishing its targeted approach from other ongoing Phase 3 trials that predominantly include HPV-negative or non-confirmed HPV16-positive HNSCC patients.
• The company's approach uses a confirmatory PCR test for HPV16-positive specific infection, contrasting with other trials that use a p16 histochemistry test which identifies infection with any of over 100 types of HPV.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for a significant market opportunity in HPV16-positive HNSCC, and progression to a pivotal Phase 3 trial, which could increase company valuation.
• Patients: Highly positive impact as Versamune HPV offers a potentially more effective and targeted treatment option for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, a disease with a severe medical need and currently limited effective treatments.
• Medical Community: Provides new, encouraging data for a challenging cancer type, potentially influencing future treatment paradigms and research directions in head and neck oncology.

Next Steps

• Continue follow-up for survival for the remaining 22 patients in the VERSATILE-002 trial.
• Conduct the randomized Phase 3 clinical trial (VERSATILE-003) for 1L r/m HPV16-positive HNSCC.
• Anticipate two interim survival data readouts from the ongoing Phase 3 study.
• Anticipate final overall survival results from the Phase 3 study.
• Develop a companion diagnostic for HPV16-positive HNSCC for inclusion in the VERSATILE-003 trial, as recommended by the FDA.

Key Dates

Recommendation

Keywords

PDS Biotechnology, PDSB, Versamune HPV, PDS0101, Head and Neck Cancer, HNSCC, HPV16-positive, Oncology, Immunotherapy, Clinical Trial, Phase 2, Phase 3, ASCO, Overall Survival, Pembrolizumab, Cancer Treatment, Biotechnology, Pharmaceutical